US regulatory status: approved.
pharma · Paroxysmal Supraventricular Tachycardia · Atrial Fibrillation · MIST
Milestone Pharmaceuticals
Milestone Pharmaceuticals drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Montreal, CA HQ
2007 Founded
123 Employees
Public company Type
MIST · NYSE Ticker
Company details
- Status
- Public
- HQ
- Montreal, CA
- Founded
- 2007
- Employees
- 123
- Programs
- 8
- Drugs
- 6
- Patents
- 12
Milestone Pharmaceuticals pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Milestone Pharmaceuticals drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
mannitol
Respiratory system (R05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Milestone Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Milestone Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved.